TY - JOUR AU - Hallek, M. AU - Fischer, K. AU - Fingerle-Rowson, G. AU - Fink, A. M. AU - Busch, R. AU - Mayer, J. PY - 2010 DA - 2010// TI - Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial JO - Lancet Lond Engl VL - 376 UR - https://doi.org/10.1016/S0140-6736(10)61381-5 DO - 10.1016/S0140-6736(10)61381-5 ID - Hallek2010 ER - TY - JOUR AU - Eichhorst, B. AU - Robak, T. AU - Montserrat, E. AU - Ghia, P. AU - Hillmen, P. AU - Hallek, M. PY - 2015 DA - 2015// TI - Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol Off J Eur Soc Med Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv303 DO - 10.1093/annonc/mdv303 ID - Eichhorst2015 ER - TY - JOUR AU - Rossi, D. AU - Terzi-di-Bergamo, L. AU - Paoli, L. AU - Cerri, M. AU - Ghilardi, G. AU - Chiarenza, A. PY - 2015 DA - 2015// TI - Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia JO - Blood. VL - 126 UR - https://doi.org/10.1182/blood-2015-05-647925 DO - 10.1182/blood-2015-05-647925 ID - Rossi2015 ER - TY - JOUR AU - Thompson, P. A. AU - Tam, C. S. AU - O’Brien, S. M. AU - Wierda, W. G. AU - Stingo, F. AU - Plunkett, W. PY - 2016 DA - 2016// TI - Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2015-09-667675 DO - 10.1182/blood-2015-09-667675 ID - Thompson2016 ER - TY - JOUR AU - Fischer, K. AU - Bahlo, J. AU - Fink, A. M. AU - Goede, V. AU - Herling, C. D. AU - Cramer, P. PY - 2016 DA - 2016// TI - Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial JO - Blood. VL - 127 UR - https://doi.org/10.1182/blood-2015-06-651125 DO - 10.1182/blood-2015-06-651125 ID - Fischer2016 ER - TY - JOUR AU - Chai-Adisaksopha, C. AU - Brown, J. R. PY - 2017 DA - 2017// TI - FCR achieves long-term durable remissions in patients with IGHV-mutated CLL JO - Blood. VL - 130 UR - https://doi.org/10.1182/blood-2017-07-731588 DO - 10.1182/blood-2017-07-731588 ID - Chai-Adisaksopha2017 ER - TY - JOUR AU - Böttcher, S. AU - Ritgen, M. AU - Fischer, K. AU - Stilgenbauer, S. AU - Busch, R. M. AU - Fingerle-Rowson, G. PY - 2012 DA - 2012// TI - Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.36.9348 DO - 10.1200/JCO.2011.36.9348 ID - Böttcher2012 ER - TY - STD TI - Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group. J Clin Oncol Off J Am Soc Clin Oncol. 2016. ID - ref8 ER - TY - JOUR AU - Kwok, M. AU - Rawstron, A. C. AU - Varghese, A. AU - Evans, P. A. S. AU - O’Connor, S. J. M. AU - Doughty, C. PY - 2016 DA - 2016// TI - Minimal residual disease is an independent predictor for 10-year survival in CLL JO - Blood. VL - 128 UR - https://doi.org/10.1182/blood-2016-05-714162 DO - 10.1182/blood-2016-05-714162 ID - Kwok2016 ER - TY - JOUR AU - Goede, V. AU - Fischer, K. AU - Busch, R. AU - Engelke, A. AU - Eichhorst, B. AU - Wendtner, C. M. PY - 2014 DA - 2014// TI - Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions JO - N Engl J Med VL - 370 UR - https://doi.org/10.1056/NEJMoa1313984 DO - 10.1056/NEJMoa1313984 ID - Goede2014 ER - TY - JOUR AU - Fischer, K. AU - Cramer, P. AU - Busch, R. AU - Böttcher, S. AU - Bahlo, J. AU - Schubert, J. PY - 2012 DA - 2012// TI - Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.2688 DO - 10.1200/JCO.2011.39.2688 ID - Fischer2012 ER - TY - JOUR AU - Bouvet, E. AU - Borel, C. AU - Obéric, L. AU - Compaci, G. AU - Cazin, B. AU - Michallet, A. -. S. PY - 2013 DA - 2013// TI - Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia JO - Haematologica. VL - 98 UR - https://doi.org/10.3324/haematol.2012.070755 DO - 10.3324/haematol.2012.070755 ID - Bouvet2013 ER - TY - JOUR AU - Hallek, M. AU - Cheson, B. D. AU - Catovsky, D. AU - Caligaris-Cappio, F. AU - Dighiero, G. AU - Döhner, H. PY - 2008 DA - 2008// TI - Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines JO - Blood. VL - 111 UR - https://doi.org/10.1182/blood-2007-06-093906 DO - 10.1182/blood-2007-06-093906 ID - Hallek2008 ER - TY - JOUR AU - Hallek, M. AU - Cheson, B. D. AU - Catovsky, D. AU - Caligaris-Cappio, F. AU - Dighiero, G. AU - Döhner, H. PY - 2018 DA - 2018// TI - iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL JO - Blood. VL - 131 UR - https://doi.org/10.1182/blood-2017-09-806398 DO - 10.1182/blood-2017-09-806398 ID - Hallek2018 ER - TY - STD TI - Boettcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch R, Fingerle-Rowson GR, et al. Minimal residual disease (MRD) re-growth kinetics are an independent predictor for progression free survival (PFS) in chronic lymphocytic leukemia (CLL) and are related to biologically defined CLL-subgroups– results from the CLL8 trial of the German CLL study group (GCLLSG). Blood. 2011;118:1777–7. ID - ref15 ER - TY - JOUR AU - Bagnara, D. AU - Kaufman, M. S. AU - Calissano, C. AU - Marsilio, S. AU - Patten, P. E. M. AU - Simone, R. PY - 2011 DA - 2011// TI - A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease JO - Blood. VL - 117 UR - https://doi.org/10.1182/blood-2010-12-324210 DO - 10.1182/blood-2010-12-324210 ID - Bagnara2011 ER - TY - JOUR AU - Tam, C. S. AU - O’Brien, S. AU - Wierda, W. AU - Kantarjian, H. AU - Wen, S. AU - Do, K. -. A. PY - 2008 DA - 2008// TI - Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia JO - Blood. VL - 112 UR - https://doi.org/10.1182/blood-2008-02-140582 DO - 10.1182/blood-2008-02-140582 ID - Tam2008 ER - TY - JOUR AU - Rawstron, A. C. AU - Villamor, N. AU - Ritgen, M. AU - Böttcher, S. AU - Ghia, P. AU - Zehnder, J. L. PY - 2007 DA - 2007// TI - International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia JO - Leukemia. VL - 21 UR - https://doi.org/10.1038/sj.leu.2404584 DO - 10.1038/sj.leu.2404584 ID - Rawstron2007 ER - TY - JOUR AU - Rawstron, A. C. AU - Böttcher, S. AU - Letestu, R. AU - Villamor, N. AU - Fazi, C. AU - Kartsios, H. PY - 2013 DA - 2013// TI - Improving efficiency and sensitivity: European research initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL JO - Leukemia. VL - 27 UR - https://doi.org/10.1038/leu.2012.216 DO - 10.1038/leu.2012.216 ID - Rawstron2013 ER - TY - JOUR AU - Rawstron, A. C. AU - Fazi, C. AU - Agathangelidis, A. AU - Villamor, N. AU - Letestu, R. AU - Nomdedeu, J. PY - 2016 DA - 2016// TI - A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European research initiative on CLL study JO - Leukemia. VL - 30 UR - https://doi.org/10.1038/leu.2015.313 DO - 10.1038/leu.2015.313 ID - Rawstron2016 ER - TY - JOUR AU - Eichhorst, B. AU - Fink, A. -. M. AU - Bahlo, J. AU - Busch, R. AU - Kovacs, G. AU - Maurer, C. PY - 2016 DA - 2016// TI - First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)30051-1 DO - 10.1016/S1470-2045(16)30051-1 ID - Eichhorst2016 ER - TY - JOUR AU - Maertens, J. AU - Cesaro, S. AU - Maschmeyer, G. AU - Einsele, H. AU - Donnelly, J. P. AU - Alanio, A. PY - 2016 DA - 2016// TI - ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients JO - J Antimicrob Chemother VL - 71 UR - https://doi.org/10.1093/jac/dkw157 DO - 10.1093/jac/dkw157 ID - Maertens2016 ER - TY - JOUR AU - Phair, J. AU - Muñoz, A. AU - Detels, R. AU - Kaslow, R. AU - Rinaldo, C. AU - Saah, A. PY - 1990 DA - 1990// TI - The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS cohort study group JO - N Engl J Med VL - 322 UR - https://doi.org/10.1056/NEJM199001183220304 DO - 10.1056/NEJM199001183220304 ID - Phair1990 ER - TY - STD TI - Fink AM, Bahlo J, Sandra R, Al-Sawaf O, Aldaoud A, Hebart H, et al. Lenalidomide maintenance after front line therapy substantially prolongs progression free survival in high risk CLL: interim results of a phase 3 study (CLL M1 study of the German CLL study group). Blood. 2016;128:229–9. ID - ref24 ER - TY - JOUR AU - Chanan-Khan, A. A. AU - Zaritskey, A. AU - Egyed, M. AU - Vokurka, S. AU - Semochkin, S. AU - Schuh, A. PY - 2017 DA - 2017// TI - Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial JO - Lancet Haematol VL - 4 UR - https://doi.org/10.1016/S2352-3026(17)30168-0 DO - 10.1016/S2352-3026(17)30168-0 ID - Chanan-Khan2017 ER - TY - JOUR AU - Shanafelt, T. D. AU - Ramsay, A. G. AU - Zent, C. S. AU - Leis, J. F. AU - Tun, H. W. AU - Call, T. G. PY - 2013 DA - 2013// TI - Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL) JO - Blood. VL - 121 UR - https://doi.org/10.1182/blood-2012-12-470005 DO - 10.1182/blood-2012-12-470005 ID - Shanafelt2013 ER - TY - JOUR AU - Ramsay, A. G. AU - Clear, A. J. AU - Fatah, R. AU - Gribben, J. G. PY - 2012 DA - 2012// TI - Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer JO - Blood. VL - 120 UR - https://doi.org/10.1182/blood-2012-02-411678 DO - 10.1182/blood-2012-02-411678 ID - Ramsay2012 ER - TY - JOUR AU - Kater, A. P. AU - Tonino, S. H. AU - Egle, A. AU - Ramsay, A. G. PY - 2014 DA - 2014// TI - How does lenalidomide target the chronic lymphocytic leukemia microenvironment? JO - Blood. VL - 124 UR - https://doi.org/10.1182/blood-2014-05-578286 DO - 10.1182/blood-2014-05-578286 ID - Kater2014 ER - TY - JOUR AU - Strati, P. AU - Keating, M. J. AU - Burger, J. A. AU - O’Brien, S. M. AU - Wierda, W. G. AU - Estrov, Z. PY - 2017 DA - 2017// TI - Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia JO - Haematologica. VL - 102 UR - https://doi.org/10.3324/haematol.2017.171561 DO - 10.3324/haematol.2017.171561 ID - Strati2017 ER - TY - JOUR AU - Dubovsky, J. A. AU - Beckwith, K. A. AU - Natarajan, G. AU - Woyach, J. A. AU - Jaglowski, S. AU - Zhong, Y. PY - 2013 DA - 2013// TI - Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes JO - Blood. VL - 122 UR - https://doi.org/10.1182/blood-2013-06-507947 DO - 10.1182/blood-2013-06-507947 ID - Dubovsky2013 ER - TY - JOUR AU - Niemann, C. U. AU - Herman, S. E. M. AU - Maric, I. AU - Gomez-Rodriguez, J. AU - Biancotto, A. AU - Chang, B. Y. PY - 2016 DA - 2016// TI - Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by Ibrutinib--findings from an investigator-initiated phase II study JO - Clin Cancer Res Off J Am Assoc Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1965 DO - 10.1158/1078-0432.CCR-15-1965 ID - Niemann2016 ER - TY - JOUR AU - Podhorecka, M. AU - Goracy, A. AU - Szymczyk, A. AU - Kowal, M. AU - Ibanez, B. AU - Jankowska-Lecka, O. PY - 2017 DA - 2017// TI - Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number JO - Oncotarget. VL - 8 UR - https://doi.org/10.18632/oncotarget.16148 DO - 10.18632/oncotarget.16148 ID - Podhorecka2017 ER - TY - JOUR AU - Long, M. AU - Beckwith, K. AU - Do, P. AU - Mundy, B. L. AU - Gordon, A. AU - Lehman, A. M. PY - 2017 DA - 2017// TI - Ibrutinib treatment improves T cell number and function in CLL patients JO - J Clin Invest VL - 127 UR - https://doi.org/10.1172/JCI89756 DO - 10.1172/JCI89756 ID - Long2017 ER - TY - JOUR AU - Ysebaert, L. AU - Gross, E. AU - Kühlein, E. AU - Blanc, A. AU - Corre, J. AU - Fournié, J. J. PY - 2010 DA - 2010// TI - Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy JO - Leukemia. VL - 24 UR - https://doi.org/10.1038/leu.2010.89 DO - 10.1038/leu.2010.89 ID - Ysebaert2010 ER - TY - STD TI - Lad D, Hoeppli R, Huang Q, Garcia R, Xu L, Toze C, et al. Regulatory T-cells drive immune dysfunction in CLL. Leuk Lymphoma. 2017:1–4. ID - ref35 ER - TY - JOUR AU - Rissiek, A. AU - Schulze, C. AU - Bacher, U. AU - Schieferdecker, A. AU - Thiele, B. AU - Jacholkowski, A. PY - 2014 DA - 2014// TI - Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia JO - Int J Cancer VL - 135 UR - https://doi.org/10.1002/ijc.28884 DO - 10.1002/ijc.28884 ID - Rissiek2014 ER - TY - JOUR AU - Mpakou, V. E. AU - Ioannidou, H. -. D. AU - Konsta, E. AU - Vikentiou, M. AU - Spathis, A. AU - Kontsioti, F. PY - 2017 DA - 2017// TI - Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia JO - Leuk Res VL - 60 UR - https://doi.org/10.1016/j.leukres.2017.07.004 DO - 10.1016/j.leukres.2017.07.004 ID - Mpakou2017 ER - TY - JOUR AU - Joffe, E. AU - Ariela Arad, N. AU - Bairey, O. AU - Fineman, R. AU - Ruchlemer, R. AU - Rahimi-Levene, N. PY - 2018 DA - 2018// TI - Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival JO - Hematol Oncol VL - 36 UR - https://doi.org/10.1002/hon.2444 DO - 10.1002/hon.2444 ID - Joffe2018 ER - TY - STD TI - Shanafelt TD, Wang V, Kay NE, Hanson CA, O’Brien SM, Barrientos JC, et al. A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912). Blood. 2018;132(Suppl 1):LBA–4–LBA–4. ID - ref39 ER - TY - JOUR AU - Strati, P. AU - Keating, M. J. AU - O'Brien, S. M. AU - Burger, J. AU - Ferrajoli, A. AU - Jain, N. AU - Tambaro, F. P. AU - Estrov, Z. AU - Jorgensen, J. AU - Challagundla, P. AU - Faderl, S. H. AU - Wierda, W. G. PY - 2014 DA - 2014// TI - Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2013-11-538116 DO - 10.1182/blood-2013-11-538116 ID - Strati2014 ER - TY - JOUR AU - Smallwood, D. T. AU - Apollonio, B. AU - Willimott, S. AU - Lezina, L. AU - Alharthi, A. AU - Ambrose, A. R. AU - De Rossi, G. AU - Ramsay, A. G. AU - Wagner, S. D. PY - 2016 DA - 2016// TI - Extracellular vesicles released by CD40/IL-4-stimulated CLL cells confer altered functional properties to CD4+ T cells JO - Blood VL - 128 UR - https://doi.org/10.1182/blood-2015-11-682377 DO - 10.1182/blood-2015-11-682377 ID - Smallwood2016 ER - TY - JOUR AU - Aguilar-Hernandez, M. M. AU - Blunt, M. D. AU - Dobson, R. AU - Yeomans, A. AU - Thirdborough, S. AU - Larrayoz, M. AU - Smith, L. D. AU - Linley, A. AU - Strefford, J. C. AU - Davies, A. AU - Johnson, P. M. W. AU - Savelyeva, N. AU - Cragg, M. S. AU - Forconi, F. AU - Packham, G. AU - Stevenson, F. K. AU - Steele, A. J. PY - 2016 DA - 2016// TI - IL-4 enhances expression and function of surface IgM in CLL cells JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2015-11-682906 DO - 10.1182/blood-2015-11-682906 ID - Aguilar-Hernandez2016 ER - TY - JOUR AU - Wang, W. e. n. -. T. i. n. g. AU - Zhu, H. u. a. -. Y. u. a. n. AU - Wu, Y. u. -. J. i. e. AU - Xia, Y. i. AU - Wu, J. i. a. -. Z. h. u. AU - Wu, W. e. i. AU - Liang, J. i. n. -. H. u. a. AU - Wang, L. i. AU - Fan, L. e. i. AU - Li, J. i. a. n. -. Y. o. n. g. AU - Xu, W. e. i. PY - 2018 DA - 2018// TI - Elevated absolute NK cell counts in peripheral blood predict good prognosis in chronic lymphocytic leukemia JO - Journal of Cancer Research and Clinical Oncology VL - 144 UR - https://doi.org/10.1007/s00432-017-2568-2 DO - 10.1007/s00432-017-2568-2 ID - Wang2018 ER -